Amgen Inc. Stock News

"The Dow® [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation.is also a consideration.�

Amgen's shares surged after management's earnings call comments about the phase 2 trial of obesity candidate MariTide. These comments and previous phase 2 data point to the increasing possibility of A

The pharmaceutical sector mainstay published its first-quarter results. These beat on both the top and bottom lines.

Amgen (AMGN) beats first-quarter 2024 estimates for earnings and sales. Amgen is "very encouraged" by interim data from the phase II study on obesity candidate MariTide.

Amgen (AMGN) sales are higher after early results from a study of an obesity drug. Renita Young discusses this as the Amgen CEO is “very encouraged” by the results of the obesity drug study.

Amgen Inc (NASDAQ:AMGN, ETR:AMG) shares gained almost 13% at about $314 in early trade on Friday after the drugmaker said it was “very encouraged” by interim trial data for its experimental weight

U.S. stock futures were solidly higher Friday morning as investors digested a slew of earnings reports and awaited the monthly U.S. employment report.

Friday stock-index futures are looking chipper, given an extra boost by a nonfarm payrolls report that pointed to a cooling labor market and lower wage inflation.

Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its e

U.S. drugmaker Amgen's shares jumped 13% to $316.26 premarket on Friday as the company teased encouraging data for its experimental obesity drug, igniting investor hopes but leaving Wall Street frustr

The company is trying to carve a niche in a rapidly growing obesity-drug market that's currently dominated by Eli Lilly and Novo Nordisk.

Amgen (AMGN) shares surged more than 14% in extended-hours trading on Thursday after the biopharmaceutical giant posted quarterly earnings that came in ahead of Wall Street expectations and provided a

Amgen, Inc. (NASDAQ:AMGN ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Justin Claeys - VP, IR Robert Bradway - Chairman, CEO & President James Bradner - EVP, Research

The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates

Shares of Amgen Inc. rallied more than 11% in the extended session Thursday after the drugmaker posted adjusted earnings above expectations and said that plans for further trials for its weight-loss d